Intervención Farmacéutica Educativa en pacientes que finalizaron el tratamiento contra la lepra / Educational pharmaceutical intervention in leprosy patients who have completed treatment

Introducción: En su rol de educador sanitario el farmacéutico realiza Intervenciones puntuales en enfermedades crónicas como la Intervención Farmacéutica Educativa (IFE) que puede ser aplicada en la Unidad de Salud de la Familia. (USF) . Objetivo: Evaluar la IFE en pacientes con lepra que finalizaron el tratamiento farmacológico entre 2011 y 2017 en Unidades de Salud de la Familia (USF) de cinco distritos del departamento central. Método: Estudio cuasi experimental, participaron 34 pacientes que finalizaron el tratamiento farmacológico contra la lepra. Se realizaron tres entrevistas domiciliarias con cada uno de ellos. Se utilizó un cuestionario de elaboración propia para medir conocimientos sobre la enfermedad, tratamiento y transmisión, mientras que para medir calidad de vida se utilizó el cuestionario SF-36 antes y después de la IFE. Resultados: En la tercera entrevista los pacientes mejoraron conocimientos, se obtuvieron mayores porcentajes de respuestas correctas en ítems como, reacciones de la lepra 100%, causas de las reacciones 82,4 %, frecuencia de control médico posterior al tratamiento 61,8%, duración del seguimiento 97%, manifestación de signos de lepra en contactos hasta 10 años después del contagio 97,1% y evaluación de contactos por personal de salud 97,1%. En el item estado de salud general mejoró la puntuación. Conclusiones: Los resultados han demostrado que los pacientes que finalizaron el tratamiento contra la lepra intervenidos, mejoraron sus conocimientos en ciertos aspectos. Esto evidencia la utilidad de la IFE como estrategia de educación sanitaria que podría implementarse en Unidades de Salud de la Familia. (AU)

Introduction: In his role as health educator, the pharmacist carries out specific interventions in chronic diseases such as the Educational Pharmaceutical Intervention (EPI) that can be applied in the Family Health Unit. (FHU) Objective: To evaluate (EPI) in patients with leprosy who completed pharmacological treatment between 2011 and 2017 in Family Health Units (FHU) of five districts of the central department. Method: It was carried out a quasi-experimental study in which 34 patients who completed pharmacological treatment against leprosy participated. Three home interviews were conducted with each patient. A self-made questionnaire was used to measure knowledge about the disease, treatment, transmission and quality of life through the SF-36 questionnaire before and after EPI. Results: In the third interview, the patients improved their knowledge; higher percentages of correct answers were obtained in items such as leprosy reactions 100%, causes of the reactions 82.4%, frequency of medical control after treatment 61.8%, duration of follow-up 97%, manifestation of signs of leprosy in contacts up to 10 years after infection 97.1% and evaluation of contacts by health personnel 97.1%. The score improved in the general health item. Conclusions: The results have shown that patients who completed leprosy treatment and underwent intervention improved their knowledge in certain aspects. This evidences the usefulness of IFE as a health education strategy and could be implemented in Family Health Units. (AU)

Papel del farmacéutico comunitario costarricense en quimioterapia preventiva de parasitosis intestinal. Estudio exploratorio / Role of the Costa Rican community pharmacist in preventive chemotherapy of intestinal parasitosis. Exploratory study

Objetivo: Identificar intervenciones farmacéuticas, en quimioterapia preventiva de parasitosis intestinal, que promuevan la prevención de esta enferme-dad y el uso efectivo y seguro de los antiparasitarios. Método: Estudio de opinión exploratorio, descriptivo transversal y multicéntrico donde se entrevistó, de forma presencial mediante un instrumento diseñado para tal fin, a 49 farmacéuticos comunitarios. Resultado: De la totalidad de los farmacéuticos comunitarios entrevistados, un 89.80% (n=44) comentó ofertar el servicio de indicación farmacéutica en caso de quimioterapia preventiva de parasitosis intestinal. Como parte de las intervenciones realizadas destacaron: derivación al médico u otro profesional de salud según criterios específicos (100.00%), dispensación de un medicamento antiparasitario (93.18%) y brindar recomendaciones higiénicas y dietéticas (79.55%). El albendazol y la nitazoxanida fueron los principales medicamentos indicados y dispensados. Conclusión: Se evidencia la importancia del papel del farmacéutico comunitario costarricense, en quimioterapia preventiva de parasitosis intestinal, para la muestra estudiada, cuyas acciones favorecen el uso racional de antiparasitarios y la prevención de las parasitosis. (AU)

Objective: To identify pharmacist interventions, in preventive chemotherapy for intestinal parasitosis that promote the prevention of intestinal parasito-sis and the effective and safe use of antiparasitic drugs. Method: It was carried out an exploratory, descripti-ve, cross-sectional and multicentre opinion study in which 49 community pharmacists were interviewed in person, using an instrument designed for this purpose. Result: Overall, 89.80% (n=44) of the community pharmacists interviewed reported offering the mi-nor ailments service in the case of preventive che-motherapy for intestinal parasitosis. Interventions included: referral to a physician or other health care provider according to criteria (100.00%), dispensing of an antiparasitic agent (93.18%) and hygiene and dietary recommendations (79.55%). Albenda-zole and nitazoxanide were the main medications dispensed. Conclusion: The importance of the role of the Costa Rican community pharmacist in preventive chemotherapy of intestinal parasitosis is evident according to the sample analyzed because his/her actions promote rational use of antiparasitic agents and the prevention of parasitosis.(AU)

Atencion Farmaceutica al paciente VIH en tratamiento con Dolutegravir y Lamivudina / Pharmaceutical Care for HIV patients on treatment with Dolutegravir and Lamivudine

Introducción: De acuerdo con la Organización Mundial de la Salud el Virus de la Inmunodeficiencia Humana (VIH) continúa siendo uno de los mayores problemas para la salud pública mundial. A día de hoy, la importancia de la adherencia al tratamiento continúa siendo el centro de atención de todos los profesionales sanitarios. La falta de adherencia supone un gran problema económico y sanitario. Método: Este estudio se centra en el servicio de atención farmacéutica (AF) realizado a los pacien-tes VIH en tratamiento con el comprimido coformulado dolutegravir/lamivudina (DTG/3TC) desde su comercialización en julio de 2019 hasta mayo 2021.Variables estudiadas: sexo, edad, adherencia, carga viral, recuento de linfocitos CD4, terapia anti-rretroviral (TAR) previa en paciente no naive, tratamientos concomitantes, interacciones, en pacientes no naive el motivo que ha conducido al cambio de TAR y los efectos adversos (EA) desarrollados. Fuente de datos: programa informático dispensación pacientes externos e historia clínica electrónica. Resultados: En el servicio de AF en la primera entrevista con el farmacéutico se tratan cinco aspectos: adherencia, EA, tratamientos y/o productos de herboristería concomitantes, interacciones y motivo de cambio de TAR. 62 pacientes iniciaron tratamiento con DTG/3TC: 24,1% (15/62) naive y 75,8% (47/62) no naive. El 100% de los pacientes naive presentaron una alta adherencia, solamente el 6,4% de los pacientes pretratados fueron identificados como no adherentes. Se encontró una contraindicación: hipérico. Conclusiones: Los pacientes presentan una alta adherencia, el tratamiento es efectivo y seguro. Se realiza el servicio de AF de forma eficaz. Conocemos la adherencia de nuestros pacientes y realizamos un estrecho seguimiento farmacoterapéutico. (AU)

Introduction: According to the World Health Organization, Human Immunodeficiency Virus (HIV) continues being one of the world's major public health problems. Currently, the importance of adherence to treatment continues being the focus of attention of health professionals. Lack of adherence is a major economic and health problem. Method: This study focuses on the pharmaceutical care service performed on all HIV patients (naive and non-naive) on treatment with the coformulated tablet dolutegravir/lamivudine (DTG/3TC) from its commercialization in July 2019 until May 2021. Variables studied: sex, age, adherence, viral load, CD4 lymphocyte count, previous antiretroviral therapy (ART) in non-naïve patients, concomitant treatments, interactions, the reason that led to the change of ART in non-naïve patient and the adverse effects developed. Results: In the first interview with the pharmacist in the pharmaceutical care service, five fundamental aspects are discussed: adherence, adverse effects, concomitant treatments and/or herbal products, interactions and reason for changing antiretroviral drugs in non-naive patients. 62 patients started treatment with DTG/3TC: 24.1% (15/62) naive and 75.8% (47/62) no naive. 100% of naive patients were highly adherent, only 6.4% of pre-treated patients were identified as non-adherent. Only one contraindication was found: hypericum. Conclusions: Patients are highly adherent, the treatment is effective and safe. The pharmaceutical care service is carried out efficiently. We are aware of our patients' adherence and carry out close phar-macotherapeutic monitoring. (AU)

Atención Farmacéutica, Determinantes sociales de la Salud y Comunidad: nuevo paradigma / Pharmaceutical Care, Social Determinants of Health and Community: a new paradigm

Este trabajo analiza las limitaciones de la concep-tualización actual de la Atención Farmacéutica, revisando los distintos enfoques comunitarios centrados en los Determinantes Sociales de la Salud (DSS) y propone una evolución hacia la Atención Farmacéutica Comunitaria, definida como i) la participación activa de la farmacia en la asistencia a su comunidad a través del mapeo de, la coordinación y la derivación hacia otros recur-sos y profesionales de dentro y fuera del sistema sanitario, ii) el diagnóstico de salud de su barrio y iii) la catalización de procesos comunitarios, a fin de conseguir resultados que mejoren la calidad de vida del paciente y de su comunidad. De este modo, los autores proponen un nuevo paradigma de Farmacia Catalizadora de Salud Comunitaria. (AU)

This paper analyzes the limitations of the current conceptualization of Pharmaceutical Care, review-ing the different community approaches focused on the Social Determinants of Health (SDH) and proposes an evolution towards Community Phar-maceutical Care, defined as i) active participation of the pharmacy in assisting its community through mapping, coordination and referral to other resourc-es and professionals inside and outside the health system, ii) the health diagnosis of its neighborhood and iii) the catalysation of community processes in order to achieve results that improve the quality of life of the patient and its community. In this way, the authors propose a new paradigm of the Pharmacy as a catalyst for the Community Health. (AU)

Mejora de la Calidad de las Publicaciones y Avance en los Paradigmas de la Investigación en Farmacia Práctica Clínica y Social: La Declaración de Granada / Improving the Quality of Publications in and Advancing the Paradigms of Clinical and Social Pharmacy Practice Research: The Granada Statements

La farmacia y las ciencias farmacéuticas abarcan una serie de disciplinas diferentes. La farmacia práctica se ha definido como "la disciplina científica que estudia los diferentes aspectos de la práctica de la farmacia y su impacto en los sistemas sanitarios, el uso de los medicamentos y la atención al paciente". Así pues, los estudios sobre la farmacia práctica abarcan tanto elementos de farmacia clínica como de farmacia social. Como cualquier otra disciplina científica, la farmacia práctica clínica y social difunde los resultados de la investigación mediante revistas científicas. Los editores de revistas de farmacia clínica y farmacia social tienen un papel en la promoción de la disciplina mediante la mejora de la calidad de los artículos publicados. Al igual que ha ocurrido en otras áreas sanitarias (medicina y enfermería), un grupo de editores de revistas de farmacia práctica clínica y social se reunió en Granada, España, para debatir cómo las revistas podrían contribuir a fortalecer la farmacia práctica como disciplina. El resultado de esa reunión se recogió en esta Declaración de Granada, que comprende 18 recomendaciones agrupadas en seis temas: el uso adecuado de la terminología, los resúmenes con impacto, las revisiones por pares requeridas, la dispersión de revistas, un uso más eficaz y prudente de los indicadores bibliométricos de revistas y artículos, y la selección por parte de los autores de la revista de farmacia práctica más adecuada para presentar sus trabajos. (AU)

Pharmacy and pharmaceutical sciences embrace a series of different disciplines. Pharmacy practice has been defined as “the scientific discipline that studies the different aspects of the practice of pharmacy and its impact on health care systems, medicine use, and patient care”. Thus, pharmacy practice studies embrace both clinical pharmacy and social phar-macy elements. Like any other scientific discipline, clinical and social pharmacy practice disseminates research findings using scientific journals. Clinical pharmacy and social pharmacy journal editors have a role in promoting the discipline by enhancing the quality of the articles published. As has occurred in other health care areas (i.e., medicine and nursing), a group of clinical and social pharmacy practice journal editors gathered in Granada, Spain to discuss how journals could contribute to strengthening pharmacy practice as a discipline. The result of that meeting was compiled in these Granada Statements, which comprise 18 recommendations gathered into six topics: the appropriate use of terminology, impactful abstracts, the required peer reviews, journal scattering, more effective and wiser use of journal and article performance metrics, and authors’ selection of the most appropriate pharmacy practice journal to submit their work. (AU)

Oferta de servicios de atención farmacéutica: clave para un nuevo modelo de servicios de salud / Supply of pharmaceutical care services: The key to a new model of health services

La colaboración interdisciplinar entre profesionales sanitarios es esencial para mejorar los resultados en salud de la población. Las capacidades que poseen los farmacéuticos les convierten en profesionales que pueden contribuir al control integral de la farmacoterapia en coordinación con otros profesionales de la salud. El Consejo de Europa aprobó la resolución CM/Res(2020)3 sobre implementación de la atención farmacéutica en el sistema sanitario para promover el uso apropiado y seguro de los medicamentos. Entre las actividades a realizar mediante el proceso de atención farmacéutica destaca la detección de problemas relacionados con la farmacoterapia como son las contraindicaciones, duplicidades, errores de prescripción, interacciones, etc. La intervención farmacéutica en ese ámbito requiere establecer un marco de colaboración interprofesional adecuado. En el presente artículo se comentan los aspectos a abordar para afrontar el cambio de modelo hacia una farmacia asistencial, con una mayor integración e implicación en el sistema, todo ello bajo el amparo del Consejo de Europa.

Interdisciplinary collaboration between health professionals is essential to improve health outcomes. The competences of pharmacists make them professionals capable of contributing to the comprehensive management of pharmacotherapy in collaboration with other healthcare professionals. The Council of Europe adopted resolution CM/Res(2020)3 on implementation of pharmaceutical care for the benefit of patients and health services in order to promote the appropriate and safe use of medicines. One of the activities to be carried out through the pharmaceutical care process is the detection of drug related problems, such as contraindications, duplications, prescription errors, interactions, etc. In many cases, it involves regular patient follow-up and needs an evaluation of the interventions performed, requiring the establishment of an appropriate interprofessional collaboration framework. This article discusses the issues to be addressed to face the change of model towards a care-based pharmacy.

Pharmaceutical care during COVID-19 pandemic: challenges and perspectives

Abstract COVID-19 (SARS-CoV-2) pandemic is raising many questions about the future of face-to-face interactions. The possible changes on healthcare delivery may provoke a long term disruption on pharmaceutical assistance requiring new approaches to provide pharmaceutical services. The proposal of pharmaceutical care is patient oriented, and its activities include different forms of interaction. The emergence of COVID-19 puts to the test all the efforts to reposition pharmaceutical care in the set of clinical activities. Now, the pharmaceutical consultations and group activities, which played a fundamental role in the reformulation of pharmacy practices, must be revised in order to reduce the risk of patient agglomeration and contamination. Several researchers suggest technology use to intermediate health care assistance. However, few studies had rigorously analyzed the effectiveness of virtual health care on the pharmaceutical field. Innovating the pharmacy workflow, during the course of a crisis like COVID-19, is the current challenge addressed to all pharmacists. This unforeseen situation requires us to reconsider our plans and actions. It will be necessary resilience, courage and creativity to achieve a consistent attitude, which provides a quick response to the health care needs in this time of crisis.

Pharmacists’ roles in mental healthcare: Past, present and future

Mental illnesses cause significant disease burden globally, with medicines being a major modality of treatment for most mental illnesses. Pharmacists are accessible and trusted healthcare professionals who have an important role in supporting people living with mental illness. This commentary discusses the role of pharmacists in mental healthcare, as part of multidisciplinary teams, the current evidence to support these roles, and the training, remuneration and policy changes needed to recognize these roles and embed pharmacists as core members of the mental healthcare team (AU)

30 años de la Revista OFIL/ILAPHAR. Revisión temática / 30 years of the OFIL/ILAPHAR Magazine. Thematic review

Objetivos: Recopilar y comentar los artículos más relevantes publicados en la Revista OFIL/ILAPHAR durante los 30 años desde creación, comparándolos con las publicaciones actuales, remarcando su importancia y aplicación.Material y métodos: Se trata de una revisión del total de los artículos disponibles en la página Web www.revistadelaofil.org, tomándose en cuenta los artículos clasificados como editoriales, cartas al editor, originales, revisiones y casos clínicos.Resultados: Se clasificaron los artículos por temas, sugiriéndose la lectura de algunos artículos por cada tema. Se pudieron encontrar artículos publicados en los inicios de la revista y que aún siguen siendo vigentes en su contenido y aplicación. Es también significativo el aporte de líderes farmacéuticos de Ibero Latinoamérica quienes dejaron asentados en sus artículos sus experiencias pero principalmente su pasión por la profesión farmacéutica.Conclusión: La revisión realizada ha servido para poder conocer cómo ha evolucionado la Revista OFIL/ILAPHAR pero también para conocer cuál ha sido la transición de los conocimientos en el mundo farmacéutico en los últimos 30 años. Recomendamos su lectura para conocer nuestra historia científica, la misma que debemos seguir engrosando con rigurosidad. (AU)

Objectives: Compile and comment on the most relevant articles published in the OFIL Magazine during the 30 years of its creation, comparing it with current publications, highlighting its importance and application.Material and methods: This article is a review of all the articles available on the OFIL Journal website www.revistadelaofil.org, considering articles classified as editorials, letters to the editor, originals, reviews, and clinical cases.Results: Articles were classified by topic, suggesting the reading of some articles for each topic. Articles published in the early days of the journal and that are still current in its content and application. The contribution of pharmaceutical leaders from Ibero Latin America is also significant, who left their experiences but mainly their passion for the pharmaceutical profession in their articles.Conclusion: The review carried out has served to be able to know how the OFIL Magazine has evolved but also to know what the transition of knowledge has been in the pharmaceutical world in the last 30 years. We recommend reading it to learn about our scientific history, the same one that we must continue to rigorously increase. (AU)

Minor Ailment Service in Costa Rica: criteria to dispense a medicine or to refer to the physician / Servicio de Indicación Farmacéutica en Costa Rica: criterios asociados con dispensar un medicamento o derivar al médico

Introduction: Minor Ailment Service is a very common pharmaceutical service. The objective was to evaluate the criteria associated with the referral to physician or with dispensing medicines in those consultations in Costa Rica.Method: Observational descriptive cross-sectional multicenter exploratory study of: Minor Ailment Service consultations in 30 community pharmacies, and analyzed the factors associated with to refer to the physician or dispense medicines.Results: There were 1,538 consultations, of which medicines are dispensed in 92.3% of them (n=1,420), referred to the physician in 6.7% (n=103). In relation to the intervention of referring to the physician, the bivariate analysis showed a statistically significant association with them, highlighting the criteria suspected adverse drug reaction, medicines use currently for other health problem and duration of the health problem ≥7 days.Conclusions: The service is complex and shows that the pharmacist follows a series of criteria to make a decision –the referral to physician or dispensing medicines–. There are seven important criteria according to this study. However, the one that stands out is suspected adverse drug reaction, followed by medicines use currently for other health problems, duration of the health problem ≥7 days and pregnancy/lactation. (AU)

Introducción: La indicación farmacéutica es un servicio farmacéutico muy común. El objetivo fue evaluar criterios asociados con derivar al médico o dispensar.Método: Estudio exploratorio multicéntrico, descriptivo de las consultas de indicación farmacéutica en 30 farmacias comunitarias durante 8 semanas. Resultados: Hubo 1.538 consultas, de las cuales se dispensaron medicamentos en el 92,3% de ellas (n=1.420), remitidas al médico en el 6,7% (n=103). En relación con la intervención de referirse al médico, el análisis bivariado mostró una asociación estadísticamente significativa con ellos, destacando los criterios sospecha de reacción adversa a medicamentos, uso de medicamentos actualmente para otro problema de salud y duración del problema de salud ≥7 días.Conclusiones: El servicio es complejo y muestra que el farmacéutico sigue una serie de criterios para la derivación al médico o la dispensación. Hay siete criterios importantes según este estudio. Sin embargo, el que destaca es la sospecha de reacción adversa a medicamentos, seguido del uso de medicamentos actualmente para otros problemas de salud, la duración del problema de salud ≥7 días y el embarazo/lactancia. (AU)

When technology precedes regulation: the challenges and opportunities of e-pharmacy in low-income and middle-income countries.

The recent growth of medicine sales online represents a major disruption to pharmacy markets, with COVID-19 encouraging this trend further. While e-pharmacy businesses were initially the preserve of high-income countries, in the past decade they have been growing rapidly in low-income and middle-income countries (LMICs). Public health concerns associated with e-pharmacy include the sale of prescription-only medicines without a prescription and the sale of substandard and falsified medicines. There are also non-health-related risks such as consumer fraud and lack of data privacy. However, e-pharmacy may also have the potential to improve access to medicines. Drawing on existing literature and a set of key informant interviews in Kenya, Nigeria and India, we examine the e-pharmacy regulatory systems in LMICs. None of the study countries had yet enacted a regulatory framework specific to e-pharmacy. Key regulatory challenges included the lack of consensus on regulatory models, lack of regulatory capacity, regulating sales across borders and risks of over-regulation. However, e-pharmacy also presents opportunities to enhance medicine regulation-through consolidation in the sector, and the traceability and transparency that online records offer. The regulatory process needs to be adapted to keep pace with this dynamic landscape and exploit these possibilities. This will require exploration of a range of innovative regulatory options, collaboration with larger, more compliant businesses, and engagement with global regulatory bodies. A key first step must be ensuring that national regulators are equipped with the necessary awareness and technical expertise to actively oversee this e-pharmacy activity.

Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic.

The coronavirus disease-19 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus that was first detected at the end of December 2019. The epidemic has affected various regions of China in different degrees. As the situations evolve, the COVID-19 had been confirmed in many countries, and made a assessment that it can be characterized as a pandemic by the World Health Organization on March 11, 2020. Drugs are the main treatment of COVID-19 patients. Pharmaceutical service offers drug safety ensurance for COVID-19 patients. According to COVID-19 prevention and control policy and requirements, combined with series of diagnosis and treatment plans, pharmacists in the first provincial-level COVID-19 diagnosis and treatment unit in Jilin Province in Northeast China have established the management practices of drug supply and pharmaceutical care from four aspects: personnel, drugs supply management, off-label drug use management and pharmaceutical care. During the outbreak, the pharmaceutical department of THJU completed its assigned workload to ensure drug supply. So far, no nosocomial infections and medication errors have occurred, which has stabilized the mood of the staff and boosted the pharmacists' confidence in fighting the epidemic. For the treatment of COVID-19, pharmacists conducted adverse reaction monitoring and participated in the multidisciplinary consultation of COVID-19. Up to now, the COVID-19 patients admitted to THJU have not shown any new serious adverse reactions and been cured finally. The hospital pharmacy department timely adjusted the work mode, and the formed management practices is a powerful guarantee for the prevention and control of the COVID-19 epidemic. This paper summarized the details and practices of drug supply and pharmaceutical services management to provide experience for the people who involving in COVID-19 prevention and contain in other abroad epidemic areas.

Pharmacists' Patient Care Process: State "Scope of Practice" Priorities for Action.

To fully engage in the Pharmacists' Patient Care Process, pharmacists must be able to (1) participate in a Collaborative Practice Agreement, (2) order and interpret laboratory tests, (3) prescribe certain medications, (4) adapt medications, (5) administer medications, and (6) effectively delegate tasks to support staff. Each of these activities is dependent on state scope of practice laws, but these laws are not binary. Various state-level restrictions allow us to view these activities on a continuum from more restrictive to less restrictive. This continuum will allow pharmacy and public health stakeholders to identify priorities for action in their states.

Milestones in managed care pharmacy.

Managed care pharmacy has a relatively short history, but one that is defined by significant achievements. Since the late 1960s, managed care pharmacists have applied their unique skills to formulary management, clinical programs, benefit design, and contract negotiations to support patient access to life-saving therapies, while also ensuring cost-effective use of limited health care resources. Key milestones include establishing the pharmacy benefit as an essential component of the U.S. health care system, launching the Medicare Part D program, and expanding medication therapy management services. The year 2020 brings another milestone-the 25th anniversary of AMCP's flagship publication, the Journal of Managed Care + Specialty Pharmacy. This year also serves as an inflection point. As managed care pharmacy professionals prepare for change and the challenges ahead-including the imperative to address the rising costs of health care and health disparities-the use of evidence, utilization management strategies, and innovation will support our continued success. DISCLOSURES: No funding supported the writing of this commentary. The authors have nothing to disclose.

The Long Term Care Pharmacy World is Changing.

The spread of COVID-19 may change the long-term care industry in ways that will last long after the pandemic has ended, and the diligent pharmacist needs to be aware of how to adjust to those changes.